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Abstract 
Objectives: There has been considerable debate over the last few decades about creating a third class of drugs that would not require 
a prescription or not be available freely over the counter, but require a pharmacist’s consultation upon purchase.  These debates 
reignited again in 2012, when the Food and Drug Administration (FDA) held a hearing about a third class of drugs positioned as an 
expanded nonprescription drug class under the FDAs Nonprescription Safe-Use Regulatory Expansion (NSURE) Initiative.  The objective 
of this study was to determine which prescription drugs community pharmacists believe are acceptable additions to an expanded 
definition of nonprescription drugs that would be available pending pharmacists’ consultation with a patient.  
Methods: This cross-sectional study was conducted using a self-report, web-based survey administered to a national panel of 
community pharmacists.  The survey contained a list of 24 current “prescription-only” drugs which may be potential candidates for 
an expanded nonprescription drug class, based on criteria outlined by the FDA, and questions related to respondent demographic and 
practice characteristics.  The respondents were asked to indicate whether a particular drug should be marketed as a prescription drug, 
nonprescription drug or as part of an expanded non-prescription drug class. Descriptive analyses were conducted to determine the drugs that 
community pharmacists believed would be suitable additions to an expanded non-prescription drug class under the NSURE initiative. 
Results: 462 completed surveys were received.  Most respondents indicated that clopidogrel bisulfate (85.3%) and zolpidem (86.6%) should 
continue to be dispensed as prescription drugs.  Atorvastatin, metformin, and sildenafil (among others) were considered appropriate to be 
marketed as an expanded nonprescription drug, in other words, dispensed without a prescription but upon pharmacist consultation.  
Desloratadine (64.6%) and pre-natal vitamins (50.2%) were considered appropriate for nonprescription status (over-the-counter, without 
pharmacist intervention).  
Conclusions: Respondents suggested that 18 out of 24 drugs (75%) on the list provided could be categorized into an expanded class of 
nonprescription drugs.  Adding more drugs to an expanded nonprescription drug class has the potential to expand pharmacists’ 
provision of patient care under the FDA’s proposed NSURE program. 
 
 
Background 
Limited access to prescription medications due to the time 
and cost associated with a prescriber visit and safety issues 
associated with prescription to over-the-counter substitutes 
continue to be a cause for concern.1-3  As a result, there has 
been much debate over the last few decades about creating 
an expanded class of nonprescription drugs (also known as a 
third class or a “behind-the-counter (BTC)” class of drugs).4  
Such a class of medications would include those drugs that do 
not require a prescription, but require a pharmacist’s 
consultation upon purchase.5 An overview of the various drug 
classes in the United States can be found in Table 1. 
 
The third-class debate came to the forefront again with a Food 
and Drug Administration (FDA) hearing in March 2012 entitled 
“Using Innovative Technologies and Other Conditions of Safe  
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Use to Expand Which Drug Products Can Be Considered 
Nonprescription,” also known as the FDAs Nonprescription 
Safe-Use Regulatory Expansion (NSURE) Initiative.  This 
hearing repositioned a third class of drugs not as a BTC class, 
“but rather as a ‘new paradigm’ under which FDA “would 
approve certain drugs that would otherwise require a 
prescription for nonprescription use.”4 These drugs would be 
approved under conditions of safe use.4 According to the FDA, 
these “conditions of safe use, would be specific to the drug 
product and might require sale in certain pre-defined health 
care settings, such as a pharmacy” and would be decided on 
a case-by-case basis.4 For example, the patient might be 
required to consult a pharmacist, or have a diagnostic test 
performed or talk to a prescriber for the first prescription of 
the drug, but obtain subsequent refills as non-prescription.  
 
Under NSURE, it has been proposed that various technologies 
such as kiosks at pharmacies, computer algorithms or 
questionnaires on the internet, would help the patient self-
diagnose correctly. Such technologies would be able to 
recommend appropriate medications to the patient for the 
specific condition along with the drug specific conditions for 
safe use. Alternatively, pharmacists would dispense the drug 
based on the patient’s medical records and inform the patient 
about the conditions for the safe use of the drug.6 
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NSURE has not gained a strong foothold at this point. 
Additionally, the FDA denied requests to reclassify 
atorvastatin, varenicline, and sildenafil as over-the-counter in 
2015.7 The profession of pharmacy has seen, in some states, 
prescription drugs re-categorized into an expanded 
nonprescription drug class.  One example includes the 
administration of oral contraceptives in Oregon and California 
by community pharmacists without a prescription after 
pharmacists have received relevant training and conducted a 
health screening for the patient.8 Regardless, it is argued that 
pharmacists are ready for the transition of some prescription 
drugs to an expanded nonprescription class given their current 
provision of patient-care services in the form of medication 
therapy management, vaccinations, and disease state 
management.7 The opportunity for pharmacists to dispense 
drugs in an expanded nonprescription class may be an answer 
to concerns about limited access to some prescription 
medications. As such, community pharmacists are critical 
stakeholders when considering which drugs are appropriate 
for an expanded nonprescription drug class.  
 
Objective 
The objective of this study was to determine which drugs 
community pharmacists believe would be acceptable 
additions to an expanded class of nonprescription drugs.  
 
Methods 
This study utilized a cross-sectional non-experimental 
descriptive design by means of a self-administered web-based 
survey that was distributed to a national convenience sample 
of community pharmacists obtained from Delta Marketing 
Dynamics (DMD) Healthcare. Before data collection, 
exemption status was granted by the respective university’s 
Institutional Review Board.   
 
This study was a part of a larger study that assessed 
community pharmacist’s attitudes toward an expanded class 
of non-prescription drugs.  The survey contained a list of 24 
current “prescription-only” drugs that may be potential 
candidates for an expanded nonprescription drug class, 
based on criteria outlined by the FDA under the NSURE 
initiative. The list of drugs was developed using the criteria for an 
expanded non-prescription drug class outlined by the 
Department of Health and Human Services (DHHS) February 
2012 federal register notice9, based on input from content 
experts, and based on existing literature.10 Preliminary qualitative 
interviews were conducted with six local community pharmacists 
to develop a list of drugs which would suffice the FDA’s criteria for 
“conditions of safe use” under NSURE. This list of drugs was 
further refined and validated through a focus group including 
three community pharmacists, two-pharmacy practice faculty, 
and one pharmacy administration faculty at the university. 
Clopidogrel and zolpidem were added to the survey as validity 
checks to assess whether respondents understood the concept of 
an expanded definition of non-prescription drugs. It was expected 
that under no circumstance should these two drugs be 
considered as potential additions to an expanded non-
prescription drug class under the NSURE program. Respondents 
were asked to indicate whether a particular drug should be 
marketed as a prescription drug, nonprescription drug or as a 
drug in an expanded non-prescription drug class. The list of drugs 
contained the generic name, brand name, and the dosage 
form for each drug. Definitions for the three response 
categories, “Dispensed as Prescription Only”, “Dispensed as 
an Expanded Nonprescription Medication” and “Sold as 
Nonprescription Only” were provided to the respondents as 
follows: 
• Dispensed as prescription only: A prescription is required 
before the pharmacist may dispense the medication. 
• Dispensed as an expanded nonprescription medication: A 
medication dispensed under the expanded nonprescription 
drug class that would require a confirmation of diagnosis by 
the pharmacist. 
• Sold as nonprescription only: The patient may purchase the 
medication over-the-counter without pharmacist 
intervention. 
Frequencies were calculated in order to determine the number 
of pharmacists that appropriated the sale of a particular drug 
under each of the three categories (i.e., prescription-only, 
nonprescription, and expanded nonprescription drug).  
Results 
Participant Response. A total of 462 completed, useable 
responses were obtained for a resultant 16.5% response rate. 
Participants were eligible for the study only if they were 
community pharmacists (potential respondents were 
screened at the start of the survey).  
 
Respondent Demographics. The average age of the 
respondents was 49 years. The sample consisted of 272 males 
(61.4%) and was predominantly Caucasian (87.2%). Just over 
66% of respondents had a Bachelor of Pharmacy (BPharm; 
practice degree) while almost 28% had a Doctor of Pharmacy 
(PharmD). 297 (64.28%) respondents were affiliated with a 
national, state, or local professional pharmacy organization. A 
full description of respondents’ demographic characteristics is 
provided in Table 2. 
 
Respondent Practice Characteristics. Most of the respondents 
were pharmacy managers/ pharmacists-in-charge (54.3%) and 
worked in an independent pharmacy (37.8%) in a self-reported 
urban location (57.9%). The sample was representative of all 
four-census regions in the United States.11 On average, 
respondents reported to have been actively practicing 
pharmacy for nearly 24 years. In a typical week respondents 
worked an average of almost 42 hours. Respondents reported 
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that their stores fill an average of 450 prescriptions on a typical 
weekday.  
 
Respondent Classification of Drugs into Dispensing Categories: 
Majority of respondents (~85%) indicated that clopidogrel and 
zolpidem should still be dispensed as prescription drugs despite 
the presence of an expanded nonprescription drug category.  
Atorvastatin, metformin, sildenafil, montelukast, proscar, 
promethazine and tamiflu (among others) were considered 
appropriate to be marketed as drugs in an expanded non-
prescription drug class.  Desloratadine and prescription pre-natal 
vitamins were considered appropriate for nonprescription status. 
Complete results can be found in Table 3, below. 
 
Discussion 
As the FDA continues to explore ideas on expanding access to 
prescription medications, it is imperative to determine the 
drugs which would be acceptable additions to an expanded 
non-prescription drug class from a patient safety/abuse 
potential standpoint. This is the first study to determine 
suitable prescription drugs, which could be dispensed without 
a prescription under conditions of safe use as per the NSURE 
initiative. A study by Sega and Sullivan (2010) had assessed 
drugs, which would be appropriate for inclusion in a BTC 
category. However, the legislation for a BTC category is 
different from the considerations for NSURE (table 1) and 
therefore an examination of suitable additions to an 
expanded non-prescription drug class under NSURE is 
warranted. Respondents indicated that most drugs on the list 
would be acceptable to dispense as part of an expanded 
nonprescription drug class.  
 
As expected, community pharmacists indicated that 
clopidogrel and zolpidem should continue to be dispensed as 
prescription drugs. Typically, clopidogrel is indicated to 
prevent clotting of blood in the heart or any other blood 
vessels. However, side effects of this drug include internal 
bleeding. Clopidogrel is contraindicated for use with common 
drugs such as aspirin and other NSAIDs (Non-Steroidal Anti-
Inflammatory Drugs). While, zolpidem is a sedative and is 
used to treat insomnia. It is habit-forming schedule IV 
controlled substance and therefore has a potential for abuse. 
Additionally, the use of this drug may lead to severe allergic 
reactions in certain patients. Therefore, community 
pharmacists indicated that clopidogrel and zolpidem should 
remain prescription-only. 
 
On the other hand, there were two prescription-only drugs 
(desloratadine and prescription pre-natal vitamins) that 
community pharmacists suggested should be switched to 
over-the-counter (OTC) status. This indicates that respondents 
believed that there is little or no need to monitor the usage of 
these drugs in the form of a prescription or nonprescription 
with pharmacist-monitoring. Desloratadine is indicated for 
allergic rhinitis and it does not have a severe adverse events 
profile unlike some of the above-mentioned drugs. 
Additionally, other allergy medications such as cetirizine 
(which were formerly prescription-only) are now available as a 
nonprescription drug. Therefore, it is not surprising that 
respondents advocated for nonprescription sale of this drug.  
 
Community pharmacists also indicated that prescription 
prenatal vitamins should be switched to OTC status. This may 
have been because several prenatal vitamins are already 
available on the market as OTCs. These OTC prenatal vitamins 
contain smaller quantities of essential micronutrients such as 
folic acid, iron, and omega-3 fatty acids as compared to their 
prescription counterparts. Community pharmacists may have 
considered that higher quantities of these micronutrients may 
not impact pregnant women. Also, given the higher demand 
for these micronutrients during the peri-conceptual stage, 
sometimes it may be convenient for pregnant women to 
consume a higher dose once daily rather than smaller dose two 
or more times a day. 
 
Finally, the majority of community pharmacists surveyed 
indicated that ~75% of the drugs on the list would be 
acceptable additions to an expanded nonprescription drug 
category. Community pharmacists may have viewed most of 
the topically applied medications to be safe based on previous 
experience and therefore were comfortable dispensing them 
without a prescription. Pharmacists also indicated that 
epinephrine injections, asthma-rescue inhalers should be 
dispensed under an expanded non-prescription drug class. This 
may have been because these are used to rescue patients in 
life-threatening conditions. These results are in line with 
findings from the Sega and Sullivan (2010) study, which was 
conducted among pharmacists in Ohio.  
 
Results from the current study also indicated that respondents 
were comfortable dispensing statins and erectile dysfunction 
(ED) drugs without a prescription under NSURE. These results 
contrast with the findings by Sega and Sullivan where 
pharmacists did not agree with the inclusion of these drugs 
into a BTC category.10 Previously under BTC, pharmacists did 
not have access to patient medical records and therefore they 
may have not been comfortable dispensing these drugs 
without a prescription. The expanded access to these drugs 
was acceptable to community pharmacists because under 
NSURE these drugs will be potentially dispensed under 
conditions of safe use, which may include providing 
pharmacists access to patient’s medical history, laboratory 
records, and even the ability to order routine lab tests to 
monitor patient’s health status. Recently there has been a 
widespread push to increase access to cholesterol-lowering 
and ED medications especially for drugs which are nearing loss 
of patent exclusivity.7 In fact in 2007, manufacturers of an ED 
drug conducted an experiment in the United Kingdom (UK) 
where certain pharmacies could dispense the drug without a 
prescription. The patients had to present the pharmacists with 
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their medical history including cholesterol and glucose levels 
before acquiring the drug. If there is a need then pharmacists 
referred the patient to a prescriber. However, the European 
Medicines Authority (EMEA) stopped the experiment citing 
that dispensing the drug without a prescription could delay the 
diagnosis of ED.12 Respondents in the current study believed 
that placing such drugs into an expanded nonprescription 
category under the NSURE initiative would put them on a 
continuum of average risk. Pharmacists are trained and are 
largely responsible for providing clinical interventions for 
conditions such as hyperlipidemia and diabetes especially in 
the asymptomatic early stages. A growing roster of states are 
expanding the role of community pharmacists in patient 
management especially while dealing with chronic diseases. 
This may have been a key factor due to which respondents felt 
comfortable and confident listing these medications as 
expanded nonprescription drugs.       
      
Limitations 
A national community pharmacist panel was used to collect 
data for this study. Despite our recruitment letter stating that 
this study was being conducted for academic purposes, there 
is potential of self-selection bias in this study. Also, 
generalizability of this study to all pharmacists across the 
United States may be limited because this study employed a 
national convenience sample of community pharmacists.  
However, the sample was stratified by region of the country 
where the respondents practiced in order to ensure that the 
distribution of the respondents was representative of the 
distribution of community pharmacists nationally based on the 
region of practice (i.e. northeast, south, mid-west and west). 
Finally, this study employed a cross sectional and descriptive 
design and therefore causal relationships among the variables 
cannot be drawn.  
 
Conclusions 
Respondents thought most drugs on the list provided can be 
categorized into an expanded nonprescription drug class whereby 
prescriptions were not needed, but pharmacist intervention still 
was.  The existence of more drugs in such a class has the potential 
to expand pharmacists’ role in the provision of patient care.  It 
has been argued that the groundwork for pharmacists’ 
provision of drugs in a nonprescription drug class had already 
been laid.7 Making more drugs available in this category may 
also increase access to drugs currently only available by 
prescription. As the FDA continues to seek feedback from 
stakeholders in regard to which medications should be a part 
of an expanded class of nonprescription drugs, feedback from 
pharmacists is critical. 
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Table 1. Definitions of drug classes in the United States with examples 
Drug Category Definition Examples 
Prescription drugs A prescription drug requires a medical 
prescription from a physician/nurse 
practitioner in order to be dispensed 
e.g. statin medications 
Over-the-counter drugs (OTC) OTC drugs does not require a medical 
prescription to be dispensed 
e.g. multivitamin tablets 
Behind-the-counter (BTC) BTC drugs do not require a medical 
prescription but do need pharmacist 
approval before being dispensed 
e.g. pseudoephedrine, Plan B (among 
adult women), dextromethorphan 
Non-prescription safe use regulatory 
expansion (NSURE) 
NSURE drugs would not require a 
medical prescription but would be 
approved by the FDA to be dispensed 
under certain conditions of safe use 
(e.g. pharmacist reviewing patient 
medical records). This class of drugs is 
not yet approved and is still under 
consideration by the FDA. 
To be determined by the FDA 
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Table 2. Demographic and Practice Characteristics of Respondents * 
Characteristics Number of Respondents (%) 
Variable Number (%) 
Gender 
                    Men 
                    Women 
 
272 (61.4) 
171 (38.6) 
Race/Ethnicity 
                    White/Caucasian   
                    Asian/ Asian Indian 
                    Hispanic 
                    African American/Black 
                    American Indian/Alaska Native   
                    Other        
 
381 (87.2) 
32 (7.3) 
4 (0.9) 
9 (2.1) 
3 (0.7) 
8 (1.8) 
Pharmacy Training 
                    Bachelor of Pharmacy (practice degree)                                          
                    Doctor of Pharmacy 
                    Master of Science  
                    Doctor of Philosophy 
                    Other                                                                      
 
320 (66.12) 
133 (27.48) 
6 (1.24) 
3 (0.62)  
22 (4.54) 
Membership of Professional Pharmacy Organization 
                     American Pharmacists Association 
                     National Community Pharmacists Association 
                     American Society of Health-System Pharmacists 
                     National Pharmaceutical Association 
                     State Pharmacy Association 
                     Other 
 
118 (22.01) 
81 (15.14) 
9 (1.68) 
10 (1.87) 
226 (42.24) 
91 (17.01) 
Type of Pharmacy 
                    Independent 
                    Franchise  
                    Traditional Chain 
                    Supermarket with a pharmacy 
                    Mass merchandiser with a pharmacy 
                    Other     
 
168 (37.8) 
23 (5.2) 
72 (16.2) 
130 (29.3) 
41 (9.2) 
10 (2.3) 
Position in the Pharmacy 
                    Staff/Floater/Relief pharmacist 
                    Manager/Pharmacist in-charge 
                    Owner 
                    District manager 
                    Regional manger 
                    Other        
 
128 (29.0) 
240 (54.3) 
70 (15.8) 
3 (0.7) 
0 (0.0) 
1 (0.2) 
Location of Pharmacy 
                    Urban                                          
                    Rural 
 
256 (57.9) 
186 (42.1) 
Geographic Region of practice 
                     South 
                     Mid-West  
                     North East 
                     West 
 
152 (34.1) 
104 (23.3) 
108 (24.2) 
82 (18.4) 
Variable Mean (SD) 
Age (in years) 48.76 (11.27) 
Years of actively practicing pharmacy (in years) 23.59 (11.50) 
Number of hours practiced in a typical week 41.51 (7.81) 
Number of prescriptions store fills on an average weekday 449.93 (554.26) 
*Fewer than 462 responses for a given question was indicative of nonresponse for that particular category. 
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Table 3. Respondent Classification of Drugs into Dispensing Categories 
Drug Name 
Category under which the Drug should be Dispensed Total* 
Dispensed as 
Prescription Only 
Dispensed as 
Expanded 
Nonprescription 
Sold as 
Nonprescription Only  
 N % N % N % N % 
atorvastatin oral 175 39.0 266 59.2 8 1.8 449 100 
metformin oral 201 44.8 242 53.9 6 1.3 449 100 
clopidogrel bisulfate oral 383 85.3 63 14.0 3 0.7 449 100 
hydrochlorothiazide oral 106 23.6 316 70.4 27 6.0 449 100 
lisinopril oral 152 33.9 288 64.1 9 2.0 449 100 
sildenafil oral 122 27.2 298 66.5 22 6.3 448 100 
finasteride oral 154 34.4 259 57.8 35 7.8 448 100 
valacyclovir hydrochloride oral 142 31.7 279 62.3 27 6.0 448 100 
zolpidem oral 388 86.6 56 12.5 4 0.9 448 100 
clindamycin benzoyl peroxide 
topical gel 22 4.9 277 61.8 149 33.3 448 100 
bupropion SR oral 210 47.0 221 49.4 16 3.6 447 100 
Prescription pre-natal vitamins oral 18 4.0 205 45.8 225 50.2 448 100 
Eflornithine cream 101 22.5 231 51.6 116 25.9 448 100 
montelukast sodium oral 159 35.7 248 55.6 39 8.7 446 100 
albuterol inhaler 97 21.7 315 70.6 34 7.6 446 100 
desloratadine oral 9 2.0 149 33.4 288 64.6 446 100 
fluticasone cream 42 9.4 298 66.8 106 23.8 446 100 
oseltamivir oral 177 39.7 255 57.2 14 3.1 446 100 
betamethasone cream 110 24.7 287 64.3 49 3.1 446 100 
methyl prednisolone oral 243 54.5 199 44.6 4 0.9 446 100 
ondansetron oral 149 33.4 271 60.8 26 5.8 446 100 
sumatriptan oral 278 62.3 160 35.9 8 1.8 446 100 
epinephrine injection 117 26.2 288 64.6 41 9.2 446 100 
promethazine oral 124 27.8 276 61.9 46 10.3 446 100 
*Fewer than 462 responses for a given question was indicative of nonresponse for that particular category. 
 
 
 
